Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

AIMS: Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. It is unknown if this relationship holds for total (first and subsequent) events. In the ODYSSEY OUTCOMES trial in patients with recent acute coronary syndrome (ACS), the proprotein convertase subti...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur Heart J
Главные авторы: Szarek, Michael, Bittner, Vera A, Aylward, Philip, Baccara-Dinet, Marie, Bhatt, Deepak L, Diaz, Rafael, Fras, Zlatko, Goodman, Shaun G, Halvorsen, Sigrun, Harrington, Robert A, Jukema, J Wouter, Moriarty, Patrick M, Pordy, Robert, Ray, Kausik K, Sinnaeve, Peter, Tsimikas, Sotirios, Vogel, Robert, White, Harvey D, Zahger, Doron, Zeiher, Andreas M, Steg, Ph Gabriel, Schwartz, Gregory G
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Clinical Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724642/
https://ncbi.nlm.nih.gov/pubmed/33051646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa649
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы